TUDCA (tauroursodeoxycholic acid) is a bile acid supplement used primarily to support liver health, improve insulin sensitivity, and protect cells from stress-related damage. It has a long history in Chinese medicine and has gained mainstream attention for its ability to help cells fold proteins correctly, a process that, when it goes wrong, contributes to liver disease, metabolic problems, and neurodegeneration.
What TUDCA Is and How It Works
TUDCA is a natural compound your body already makes in small amounts. Your liver produces primary bile acids from cholesterol, sends them into your gut, and bacteria there convert some of them into a secondary bile acid called ursodeoxycholic acid (UDCA). When UDCA cycles back to the liver, it gets paired with the amino acid taurine to form TUDCA.
What makes TUDCA interesting as a supplement is that it acts as a “chemical chaperone” inside your cells. Every cell has a structure called the endoplasmic reticulum (ER) that folds newly made proteins into the right shapes. When that system gets overwhelmed, either from disease, toxins, or metabolic overload, misfolded proteins accumulate and trigger a stress response that can eventually kill the cell. TUDCA steps in to stabilize protein folding and dial down that stress response, reducing the signals that push cells toward programmed death. It boosts levels of proteins that protect cells while lowering levels of those that promote cell destruction.
Liver Protection and Bile Flow
Liver support is the most established use for TUDCA. Its parent compound, UDCA, is already FDA-approved for treating primary biliary cholangitis, a condition where bile ducts in the liver slowly deteriorate. TUDCA performs comparably. In a randomized, double-blind trial of patients with this condition, about 76% of those taking TUDCA achieved a significant reduction in a key liver enzyme (alkaline phosphatase) after 24 weeks, a rate statistically similar to UDCA.
For chronic active hepatitis, the results are even more striking in terms of enzyme changes. In one trial, patients taking 500 mg of TUDCA daily saw their liver enzymes drop substantially within three months: AST fell by 44%, ALT by 49%, and GGT by 38% compared to baseline. The improvements started appearing after just one month. None of the patients in that trial reported side effects.
TUDCA also shifts the overall bile acid pool in your liver toward more water-soluble, less toxic bile acids. Administering 500 to 1,500 mg daily has been shown to enrich the bile acid pool with UDCA by 34% to 41%, making bile less damaging to liver cells. This is particularly relevant if you’re dealing with cholestasis, a condition where bile flow from the liver is impaired.
Insulin Sensitivity and Metabolic Health
TUDCA has shown real promise for improving how the body responds to insulin, particularly in the liver and muscles. In a randomized trial, obese adults who took 1,750 mg of TUDCA daily for four weeks saw their liver and muscle insulin sensitivity increase by roughly 30%. Muscle cells also showed enhanced insulin signaling at the molecular level. The ability of muscles to take up glucose improved by about 34% compared to pre-treatment levels. These changes did not occur in the placebo group.
The connection between ER stress and insulin resistance is well documented in animal research. Obese mice treated with TUDCA show reduced ER stress, improved whole-body insulin sensitivity, and lower levels of fat stored in the liver. The human data, while based on a small trial of 20 people, aligns with these findings and suggests TUDCA could be a useful tool for metabolic health, especially in people carrying excess weight.
Neuroprotection and ALS
TUDCA has been studied for its ability to protect nerve cells from degeneration, with the most advanced clinical work done in amyotrophic lateral sclerosis (ALS). In a retrospective study, patients taking TUDCA had a median overall survival of 49.6 months compared to 36.2 months in the control group. Patients on higher doses (1,000 mg or more daily) had a 44% lower risk of death compared to controls and those on lower doses.
The neuroprotective mechanism ties back to TUDCA’s core function: reducing the buildup of toxic misfolded proteins that cause ER stress and oxidative damage in neurons. This same process is implicated in Huntington’s, Parkinson’s, and Alzheimer’s disease, and TUDCA has shown protective effects in laboratory models of all three.
It’s worth noting the complicated regulatory history here. In 2022, the FDA approved Relyvrio, a combination drug containing TUDCA (as taurursodiol) and sodium phenylbutyrate, for ALS treatment. However, when the larger phase 3 trial (PHOENIX) showed no statistically significant benefit over placebo, the manufacturer voluntarily pulled the drug from U.S. and Canadian markets in 2024. This doesn’t necessarily invalidate the earlier findings, but it does mean the evidence for ALS remains uncertain.
Eye and Retinal Health
A growing body of lab and animal research suggests TUDCA may protect retinal cells from degeneration. A systematic review identified studies covering retinitis pigmentosa, diabetic retinopathy, glaucoma-related damage, age-related macular degeneration, and several other retinal conditions. The common thread is that TUDCA appears to slow the loss of photoreceptors (the light-sensing cells in the retina) and protect retinal ganglion cells, whose damage leads to permanent blindness in conditions like glaucoma.
This research is still in the preclinical stage, meaning the results come from cell cultures and animal models rather than human trials. But the consistency across multiple types of retinal injury has made it an active area of investigation.
How TUDCA Compares to UDCA
Since UDCA is already a well-known prescription medication, a natural question is why someone would choose TUDCA instead. The two share nearly identical biological functions, but the addition of taurine gives TUDCA better water solubility, which translates to improved absorption and bioavailability. TUDCA also appears to have stronger antioxidant properties than its unconjugated parent compound, giving it a slight edge in reducing cellular stress and preventing cell death. In clinical trials comparing the two directly for liver conditions, their effectiveness is similar, but TUDCA’s physicochemical profile makes it the more physiologically active form.
Dosage Ranges Used in Research
Human trials have used a fairly wide range of doses depending on the condition. For chronic liver disease, 500 mg daily (split into two doses with meals) produced significant enzyme reductions over three months. For metabolic and insulin sensitivity benefits, the trial that showed a 30% improvement used 1,750 mg daily for four weeks. ALS research has used doses at or above 1,000 mg daily, with higher doses showing more pronounced survival benefits. Most supplement products on the market provide between 250 and 500 mg per capsule.
Safety and Side Effects
TUDCA is generally well tolerated. In the chronic hepatitis trial using 500 mg daily, no side effects were reported at all. In longer-term use among ALS patients, about 8% discontinued due to side effects, which were primarily gastrointestinal and mild. Only two adverse events in that group required a hospital visit, and both resolved without lasting problems. Gastrointestinal discomfort, particularly diarrhea, is the most commonly reported issue at higher doses, which is consistent with how bile acids affect the gut when taken in larger quantities.